Kapital Partner, Ewaldsgade 9, Copenhagen (2026)

21/07/2025

In the past week, the Danish biotech and healthcare sector rose 1.1%. Most notably, Ascendis Pharma announced positive 3-year data for TransCon, further consolidating the long-term benefits of its product. Furthermore, Genmab announced sales of Darzalex at USD 3.54 billion and Kesimpta at USD 1.08 billion, surpassing expectations. Genmab receives royalties of Darzalex and Kesimpta. Finally, SynAct Pharma received MSEK 17.7 after conversion of warrants, securing additional capital.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Danish biotech and healthcare sector rose 1.1%. Most notably, Ascendis Pharma announced positive 3-year data for TransCon, further consolidating the long-term benefits of its p...

16/06/2025

In the past week, the Danish biotech and healthcare sector delivered a negative return of 4.5%. Acarix received reimbursement in the U.S., while FluoGuide and Genmab presented positive results. 2cureX continues to be the odd one return-wise, with a stock price return of almost 10x year-to-date. The year-to-date return for the Danish biotech and healthcare stocks is 40.6%, including 2cureX, while it is -8.2% excluding 2cureX.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Danish biotech and healthcare sector delivered a negative return of 4.5%. Acarix received reimbursement in the U.S., while FluoGuide and Genmab presented positive results. 2cur...

10/06/2025

In the past week, the Danish biotech and healthcare sector rose 4%. Most notably, Evaxion received a grant from the Gates Foundation to design a new vaccine for polio, SynAct Pharma raised MSEK 37 via a directed rights issue, and Gubra announced a dividend of DKK 1 billion, which is more than half of the market value at the IPO just two years ago. Finally, 2CureX continues to skyrocket, rising 60% in the past week. The stock is now up more than 10x year-to-date, which has propelled the YTD return for the Danish biotech and healthcare sector to 49.8%, while the return is -6.6% without 2CureX.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Danish biotech and healthcare sector rose 4%. Most notably, Evaxion received a grant from the Gates Foundation to design a new vaccine for polio, SynAct Pharma raised MSEK 37 v...

02/06/2025

In the past week, the Danish biotech and healthcare sector did not deliver any price changes. However, 2cureX continues to skyrocket with almost 5x return year-to-date. Furthermore, Cessatech announced positive study results with CT001 against acute pain, while also raising nearly MDKK 15. Evaxion, Fluoguide, and Saniona reported their Q1 results, while Genmab and Zealand Pharma received new price targets.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Danish biotech and healthcare sector did not deliver any price changes. However, 2cureX continues to skyrocket with almost 5x return year-to-date. Furthermore, Cessatech announ...

26/05/2025

In the past week, the Danish biotech and healthcare stocks rose 7.9%, driven by 7 stocks with a return of more than 10%. Curasight, in particular, rose 65% following the completion of their rights issue, raising DKK 47 million. Moreover, Acarix’s CEO bought shares, and Danske Bank is eyeing a more than 3x potential in Zealand Pharma.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Danish biotech and healthcare stocks rose 7.9%, driven by 7 stocks with a return of more than 10%. Curasight, in particular, rose 65% following the completion of their rights i...

12/05/2025

In the past week, the Nordic biotech and healthcare stocks rose 7%. 2cureX rose 90% without any news and is now up more than 500% in the past month. Several companies released their Q1 earnings, with Genmab reporting impressive growth and Gubra with a solid guidance. Furthermore, Zealand Pharma got new price targets at more than twice their current stock price.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rose 7%. 2cureX rose 90% without any news and is now up more than 500% in the past month. Several companies released their Q1 earnings, wit...

05/05/2025

In the past week, the Nordic biotech and healthcare stocks rose 5.2%. 2Curex rose a whopping 59% without any news. The week was dominated by earnings releases and CEO predictions for 2025. Furthermore, Kempen released new price targets for Gubra and Zealand Pharma. Finally, Curasight’s MDKK 100 capital raise has started with a significant discount. See the ongoing offerings at the end of this post.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rose 5.2%. 2Curex rose a whopping 59% without any news. The week was dominated by earnings releases and CEO predictions for 2025. Furthermo...

28/04/2025

In the past week, the Nordic biotech and healthcare stocks rose 3.4%. Curasight announced the subscription price of its MDKK 100 rights issue, multiple companies reported positive clinical progress, HSBC recommends buy of a Danish giant, and SynAct Pharma saw positive patent development. Year-to-date, SynAct Pharma is the best-performing stock with a return of 123%.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rose 3.4%. Curasight announced the subscription price of its MDKK 100 rights issue, multiple companies reported positive clinical progress,...

25/04/2025

Curasight Q1-rapport er landet. Den igangværende kapitalrejsning skal løse selskabets akutte finansieringsbehov, der er tynget af et negativt cash flow til udviklingsaktiviteterne. Big pharma bliver atter nævnt som en snarlig mulighed, der kan løfte aktiekursen, og i 2025 er der flere kurstriggerevents at se frem til.

Læs mere:

Curasight Q1-rapport er landet. Den igangværende kapitalrejsning skal løse selskabets akutte finansieringsbehov, der er tynget af et negativt cash flow til udviklingsaktiviterne. Big pharma bliver atter nævnt som en snarlig mulighed, der kan løfte aktiekursen, og i 2025 er der flere kurstriggere...

22/04/2025

In the past week, the Nordic biotech and healthcare stocks declined 3%. Cessatech increased 38%, while 2Curex declined 64% although none of the stocks reported any news. FluoGuide saw progress with FG001 in one of the largest cancer markets worldwide. Furthermore, Goldman Sachs and BNP Paribas initiated new price targets significantly higher than current share prices for multiple stocks.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 3%. Cessatech increased 38%, while 2Curex declined 64% although none of the stocks reported any news. FluoGuide saw progress in on...

14/04/2025

In the past week, the Nordic biotech and healthcare stocks rebounded slightly with a 2.3% return. The most notable news includes Synact Pharma’s initiation of a phase II study and one Danish biotech stock received a new price target from Goldman Sachs at more than twice their current stock price.

Read more:

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rebounded slightly with a 2.3% return. The most notable news includes Synact Pharma’s initiation of a phase II study and one Danish biote...

07/04/2025

Curasight ønsker at rejse MDKK 100 i en fortegningsemission svarende til næsten 80% af selskabets nuværende markedsværdi. Curasight har sikret sig forhåndstegninger og garantiforpligtelser på i alt 47% af udbuddet heriblandt fra ledelsen og Curium. Pengene skal gå til betydelige udviklingsstudier af både uTRACE og uTREAT, og de endelige betingelser for kapitalrejsningen afgøres inden længe.

Læs mere:

Curasight ønsker at rejse MDKK 100 i en fortegningsemission svarende til næsten 80% af selskabets nuværende markedsværdi. Curasight har sikret sig forhåndstegninger og garantiforpligtelser på i alt 47% af udbuddet heriblandt fra ledelsen og Curium. Pengene skal gå til betydelige udviklingsstu...

Kapital Partner